Gilead Sciences, Inc. (GILD) Holdings Reduced by Investment House LLC

Investment House LLC cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,330 shares of the biopharmaceutical company’s stock after selling 3,005 shares during the period. Investment House LLC’s holdings in Gilead Sciences were worth $2,167,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Moloney Securities Asset Management LLC lifted its position in shares of Gilead Sciences by 10.0% during the first quarter. Moloney Securities Asset Management LLC now owns 5,163 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 470 shares in the last quarter. South Dakota Investment Council lifted its position in shares of Gilead Sciences by 6.2% during the first quarter. South Dakota Investment Council now owns 755,629 shares of the biopharmaceutical company’s stock worth $49,123,000 after purchasing an additional 44,080 shares in the last quarter. Smith Salley & Associates lifted its position in shares of Gilead Sciences by 9.1% during the first quarter. Smith Salley & Associates now owns 49,666 shares of the biopharmaceutical company’s stock worth $3,229,000 after purchasing an additional 4,136 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Gilead Sciences by 1,053.0% during the first quarter. Victory Capital Management Inc. now owns 220,422 shares of the biopharmaceutical company’s stock worth $14,330,000 after purchasing an additional 201,305 shares in the last quarter. Finally, Regentatlantic Capital LLC lifted its position in shares of Gilead Sciences by 26.4% during the first quarter. Regentatlantic Capital LLC now owns 42,596 shares of the biopharmaceutical company’s stock worth $2,769,000 after purchasing an additional 8,886 shares in the last quarter. Hedge funds and other institutional investors own 79.94% of the company’s stock.

In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the company’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the completion of the sale, the director now owns 34,669 shares of the company’s stock, valued at $2,270,126.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the sale, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. Insiders sold 28,602 shares of company stock worth $1,863,445 over the last 90 days. 0.20% of the stock is currently owned by company insiders.

Shares of NASDAQ GILD opened at $66.52 on Wednesday. Gilead Sciences, Inc. has a fifty-two week low of $60.32 and a fifty-two week high of $79.61. The company has a market capitalization of $84.60 billion, a P/E ratio of 10.82, a price-to-earnings-growth ratio of 0.81 and a beta of 1.14. The company has a current ratio of 3.62, a quick ratio of 3.53 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The business had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the business posted $1.48 earnings per share. Gilead Sciences’s revenue was up 3.8% compared to the same quarter last year. Research analysts predict that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.63 dividend. The ex-dividend date is Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.79%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

A number of equities analysts have recently issued reports on the stock. Credit Suisse Group assumed coverage on shares of Gilead Sciences in a research report on Monday. They set a “neutral” rating and a $70.00 target price on the stock. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Friday, May 17th. Evercore ISI reiterated a “buy” rating on shares of Gilead Sciences in a research report on Friday, May 17th. JPMorgan Chase & Co. reiterated a “buy” rating and set a $87.00 target price on shares of Gilead Sciences in a research report on Tuesday, May 7th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Monday, May 6th. Ten research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $81.00.

TRADEMARK VIOLATION NOTICE: This article was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2019/05/22/gilead-sciences-inc-gild-holdings-reduced-by-investment-house-llc.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: What are the reasons investors use put options?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.